Format

Send to

Choose Destination
Heart Fail Rev. 2019 Mar;24(2):189-197. doi: 10.1007/s10741-018-9752-6.

Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management.

Author information

1
Division of Cardiology, Lehigh Valley Health Network, 1200 S. Cedar Crest Blvd, Allentown, PA, 18103, USA. garg.medicine@gmail.com.
2
Maulana Azad Medical College, Delhi, 110092, India.
3
Division of Cardiology, Lehigh Valley Health Network, 1200 S. Cedar Crest Blvd, Allentown, PA, 18103, USA.
4
Division of Cardiology, Brown University, Providence, RI, 02903, USA.
5
Department of Internal Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA.

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common hereditary cardiomyopathy characterized by left ventricular hypertrophy and spectrum of clinical manifestation. Atrial fibrillation (AF) is a common sustained arrhythmia in HCM patients and is primarily related to left atrial dilatation and remodeling. There are several clinical, electrocardiographic (ECG), and echocardiographic (ECHO) features that have been associated with development of AF in HCM patients; strongest predictors are left atrial size, age, and heart failure class. AF can lead to progressive functional decline, worsening heart failure and increased risk for systemic thromboembolism. The management of AF in HCM patient focuses on symptom alleviation (managed with rate and/or rhythm control methods) and prevention of complications such as thromboembolism (prevented with anticoagulation). Finally, recent evidence suggests that early rhythm control strategy may result in more favorable short- and long-term outcomes.

KEYWORDS:

Antiarrhythmic agents; Atrial fibrillation; Hypertrophic cardiomyopathy; Treatment

PMID:
30456592
DOI:
10.1007/s10741-018-9752-6

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center